Skip to main content

Table 5 Cost effectiveness analysis over 2-year treatment duration

From: The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

Therapy Cost/patient (US$) QALYs gained/patient ICER (ΔC/ΔE) Comparator
Ibuprofen + PPI 4,204.10 1.11 3,787.48 No treatment
Celecoxib + PPI 4,512.80 1.37 1,187.31 Ibuprofen + PPI
Celecoxib* 4,716.80 1.24 Dominated -
Diclofenac + PPI* 4,891.60 1.17 Dominated -
Ibuprofen* 5,575.10 0.85 Dominated -
Diclofenac* 5,662.50 0.96 Dominated -
Etoricoxib + PPI 5,892.40 1.35 Dominated -
Etoricoxib 6,621.80 1.23 Dominated -
  1. *Simple dominance: Another option is less expensive and more effective
  2. ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
  3. ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option